Peng Yue
Co-Founder, CEO ReviR Therapeutics
Seminars
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics
• How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines
• How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets and attract strategic capital
• What trends can be identified from recent investments, M&A activity and deal structures to inform future strategies in RNA therapeutics
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas
• What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space
• Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic applicability of splice modulators
• What lessons can be drawn from recent investments and platform development to guide future innovation in RNA-targeted small molecules
• Finalizing development of a lead candidate targeting HTT and PMS1 splicing with support from CIRM for IND-enabling studies in Huntington’s disease to accelerate clinical readiness and unlock therapeutic potential
• Accelerating preclinical development with refined single-molecule chemistry and new functional datasets to enhance compound validation and improve translational confidence in ReviR’s lead asset
• Expanding ReviR’s pipeline with additional splicing-modulation programs in spinal muscular atrophy and Charcot-Marie-Tooth disease to broaden therapeutic reach and address unmet needs in neurodegeneration
- Finalizing development of a lead candidate targeting HTT and PMS1 splicing with support from CIRM for IND-enabling studies in Huntington’s disease to accelerate clinical readiness and unlock therapeutic potential
- Accelerating preclinical development with refined single-molecule chemistry and new functional datasets to enhance compound validation and improve translational confidence in ReviR’s lead asset
- Expanding ReviR’s pipeline with additional splicing-modulation programs in spinal muscular atrophy and Charcot Marie-Tooth disease to broaden therapeutic reach and address unmet needs in neurodegeneration
